MedTrace Logo

Sunitinib Malate and Exemestane in Treating Postmenopausal Women With Breast Cancer

NCT00931450 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2013-08-12

No results posted yet for this study

Summary

RATIONALE: Sunitinib malate and exemestane may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving sunitinib malate and exemestane before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.

PURPOSE: This randomized phase I/II trial is studying the side effects and best dose of sunitinib malate to see how well it works when given together with exemestane in treating postmenopausal women with breast cancer.

Conditions

Interventions

DRUG

exemestane

Given orally

DRUG

sunitinib malate

Given orally

OTHER

placebo

Given orally

Sponsors & Collaborators

  • Institut Català d'Oncologia

    lead OTHER

Principal Investigators

  • Sonia Pernas, MD · Institut Català d'Oncologia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-03-31
Primary Completion
2011-10-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00931450 on ClinicalTrials.gov